TOKYO -- A Japanese court ruled Tuesday in favor of a patent application by a U.S. institute on the breakthrough CRISPR-Cas9 gene-editing technique, in a win for a technology embroiled in intellectual property disputes worldwide.
If the ruling is upheld, drugmakers and other companies would be required to pay license fees to use the technique for commercial purposes.
